MX2022005083A - Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos. - Google Patents

Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.

Info

Publication number
MX2022005083A
MX2022005083A MX2022005083A MX2022005083A MX2022005083A MX 2022005083 A MX2022005083 A MX 2022005083A MX 2022005083 A MX2022005083 A MX 2022005083A MX 2022005083 A MX2022005083 A MX 2022005083A MX 2022005083 A MX2022005083 A MX 2022005083A
Authority
MX
Mexico
Prior art keywords
dry powder
powder formulations
tslp
methods
thymic stromal
Prior art date
Application number
MX2022005083A
Other languages
English (en)
Inventor
David Lechuga-Ballesteros
Emma Suzanne Cohen
Catherine Eugenie Chaillan Huntington
Susan Hoe
Prakash Manikwar
Saba Ghazvini
Kellisa Beth Hansen
Dexter Joseph D''sa
Roland Wilhelm Kolbeck
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2022005083A publication Critical patent/MX2022005083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La tecnología de la presente se relaciona, en general, con formulaciones en polvo seco de anticuerpos específicos para la linfopoyetina estromal tímica (TSLP), así como también métodos para tratar asma, con el uso de formulaciones en polvo seco, convenientemente vía administración pulmonar.
MX2022005083A 2019-10-28 2020-10-27 Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos. MX2022005083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962926833P 2019-10-28 2019-10-28
PCT/EP2020/080201 WO2021083908A1 (en) 2019-10-28 2020-10-27 Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022005083A true MX2022005083A (es) 2022-07-19

Family

ID=73030137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005083A MX2022005083A (es) 2019-10-28 2020-10-27 Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.

Country Status (15)

Country Link
US (2) US11904053B2 (es)
EP (1) EP4051708A1 (es)
JP (1) JP2022554249A (es)
KR (1) KR20220088752A (es)
CN (1) CN114867748A (es)
AR (1) AR120309A1 (es)
AU (1) AU2020376222A1 (es)
BR (1) BR112022008031A2 (es)
CA (1) CA3154999A1 (es)
CO (1) CO2022005391A2 (es)
CR (1) CR20220189A (es)
IL (1) IL292437A (es)
MX (1) MX2022005083A (es)
TW (1) TW202131947A (es)
WO (1) WO2021083908A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022223514A1 (en) * 2021-04-19 2022-10-27 Medimmune Limited An anti-tslp fab with improved stability
US20230270668A1 (en) * 2021-10-11 2023-08-31 Augmenta Bioworks, Inc. Dry formulations of anti-sars-cov-2 virus antibodies and compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02004193A (es) * 1999-10-29 2002-12-13 Inhale Therapeutic Syst Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas.
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CN107428828A (zh) 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
CA2996635A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
AU2016320748B2 (en) * 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
KR20180050320A (ko) 2015-09-09 2018-05-14 노파르티스 아게 분무-건조된 제제의 폐로의 표적화된 전달
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
JP2021510723A (ja) 2018-01-26 2021-04-30 ノバルティス アーゲー 吸入型治療薬の高用量送達

Also Published As

Publication number Publication date
AU2020376222A1 (en) 2022-06-02
JP2022554249A (ja) 2022-12-28
KR20220088752A (ko) 2022-06-28
BR112022008031A2 (pt) 2022-07-12
US11904053B2 (en) 2024-02-20
US20230201120A1 (en) 2023-06-29
CO2022005391A2 (es) 2022-08-19
CR20220189A (es) 2022-08-19
US20210121406A1 (en) 2021-04-29
CN114867748A (zh) 2022-08-05
CA3154999A1 (en) 2021-05-06
EP4051708A1 (en) 2022-09-07
TW202131947A (zh) 2021-09-01
AR120309A1 (es) 2022-02-09
WO2021083908A1 (en) 2021-05-06
IL292437A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
CR20220189A (es) Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.
MX2020006688A (es) Celulas presentadoras de antigenos artificiales y metodos de uso.
PH12015502169B1 (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
EP4234011A3 (en) Microbiota restoration therapy (mrt), compositions and methods of manufacture
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
MX2020013421A (es) Composiciones de dióxido de silicio de carbono poroso biogénico, métodos de elaboracion y uso de estas.
MX2012005782A (es) Procedimientos, composiciones y kits de liofilizacion.
MX2010001723A (es) Formulaciones de anticuerpos y moleculas de fusion-fc usando policationes.
PH12021551100A1 (en) Dried biological compositions and methods thereof
PH12018500747B1 (en) Fly ash, cement composition, and method of preparing fly ash
MX2021005157A (es) Composiciones, metodos para hacer y utilizar extracto de salvado de arroz.
MX2023004078A (es) Proteinas f de hmpv estabilizadas por prefusion.
MX2021003383A (es) Metodos para diferenciar celulas troncales mesenquimales.
GB2514741A (en) Composition for use as a paint binder
AU2018276376A1 (en) Cell culture methods
MX2020002552A (es) Métodos y composiciones para preparar proteína surfactante d (sp-d).
MY192390A (en) Method for isolation of stem cells from bone marrow using subfractionation culturing method and proliferation thereof
MX342624B (es) Formulaciones para el factor estimulante de colonia de granulocito de bovino y sus variantes.
MX2009011851A (es) Plasmidos de dna que tienen expresion y estabilidad mejoradas.
Halim Involvement of MAPK/ERK and Akt signaling pathways in the proliferation of keratinocytes cocultured with adipose-derived stem cells (ACSS)-Porous Chitosan Scaffold (PSC)
MX2022006800A (es) Particulas interferentes defectuosas.
AR104289A1 (es) Composiciones para formulaciones cosméticas de hidratación prolongada comprendiendo manteca de ucuuba con elevada concentración de ácido mirístico, así como uso de dicha formulación para la preparación de un producto cosmético con alto poder hidratante y kit